Navigation Links
Amneal Receives FDA Approval for Bethanechol Chloride Tablets, USP Using New Expedited FDA Approval Process
Date:11/29/2007

PATERSON, N.J., Nov. 29 /PRNewswire/ -- Amneal Pharmaceuticals is pleased to announce that it received US FDA approval to manufacture Bethanechol Chloride Tablets, USP in strengths of 5mg, 10mg, 25mg and 50 mg, effective November 21, 2007. Bethanechol HCl is an AA-Rated, therapeutically equivalent alternative to Urecholine(R) (a trademark of Barr Laboratories).

The Bethanechol approval represents a breakthrough for Amneal, who is one of the very first companies to submit an ANDA in the FDA's new, optional eCTD/QBR/QOS format. This application method resulted in a significantly more efficient approval evaluation process, dramatically reducing anticipated approval time. Amneal's Bethanechol eCTD application was approved just 10 months and 10 days after its January 2007 application date. All of Amneal's ANDAs since Bethanechol are being filed using the eCTD format.

Amneal will begin shipping Bethanechol in the 25mg strength as of January 4, 2008 with the other three strengths beginning in February 2008. Amneal's Bethanechol is expected to be available through wholesalers-distributors as well as directly to customers.

Amneal Pharmaceuticals LLC, headquartered in Paterson, NJ, is a USA-based firm that develops, manufacturers and distributes generic pharmaceutical products regulated and approved by the US FDA. Positioned as "Generic's New Generation," the company utilizes diverse R&D and manufacturing expertise to conceive breakthrough developments with lasting impact. Vigorous ANDA growth and broad product acquisitions are key features of Amneal's strategic growth plan, as is the company's commitment to building deep relationships with its customer base. Amneal delivers superior service levels, quality products, and dynamic value throughout the pharmaceutical industry.


'/>"/>
SOURCE Amneal Pharmaceuticals LLC
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Amneal Pharmaceuticals & Indoco Remedies Finalize Long Term Joint Venture Agreement to Develop and Market Generic Ophthalmic Pharmaceuticals
2. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
3. DaVita Receives Civil Complaint
4. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
5. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
6. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
7. Mayo Clinic Multidisciplinary Simulation Center Receives Distinction as an ACS-Accredited Education Institute
8. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
9. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
10. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
11. Prime Therapeutics Receives TIPPS Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... With chronic respiratory disorders, method cuts death risk, study ... with chronic respiratory disorders who receive early non-invasive ventilation ... likely to suffer respiratory failure or die, a Spanish ... on mechanical ventilation. All of them had high levels ...
... , , , , ... KAD ), a leading provider of home care, medical staffing, and pharmacy services ... ended June 30, 2009. , , For the ... with $26.8 million for the same period last year. Arcadia reported a ...
... The Gilchrist Institute for the Achievement Sciences, an economic ... health care reform aimed at members of Congress and the ... Gilchrist Institute Director Dr. Robert Flower states, "We are challenging ... the application that needs reform and the administration that needs ...
... 13 Insmed Inc. (Nasdaq: INSM ), a biopharmaceutical ... June 30, 2009. , , Revenues for the ... $2.7 million for the corresponding period in 2008. The increase ... IPLEX(TM) myotonic muscular dystrophy ("MMD") clinical trial recorded in the most ...
... ... introduced the supplement NourishLife speak™ which combines omega-3 and vitamin E ... A recent study published in the July issue of Alternative ... apraxia taking a combination of omega-3 and vitamin E noted significant ...
... ... proud to announce the September 1 opening of its newest office in ... population from Hoboken, Jersey City and the Newport area and our physicians ... services. The Hoboken office is partly the result of a merger with ...
Cached Medicine News:Health News:Ventilation After Breathing Tube Removal May Alter Outcomes 2Health News:Arcadia Resources Announces First Quarter Results 2Health News:Arcadia Resources Announces First Quarter Results 3Health News:Arcadia Resources Announces First Quarter Results 4Health News:Arcadia Resources Announces First Quarter Results 5Health News:Arcadia Resources Announces First Quarter Results 6Health News:Arcadia Resources Announces First Quarter Results 7Health News:Arcadia Resources Announces First Quarter Results 8Health News:Arcadia Resources Announces First Quarter Results 9Health News:Arcadia Resources Announces First Quarter Results 10Health News:Arcadia Resources Announces First Quarter Results 11Health News:Arcadia Resources Announces First Quarter Results 12Health News:Arcadia Resources Announces First Quarter Results 13Health News:Arcadia Resources Announces First Quarter Results 14Health News:Arcadia Resources Announces First Quarter Results 15Health News:Institute Chastises Congress on Health Care Reforms, Offers Five-Point Program for Reducing Health Care Costs by 50% 2Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 2Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 3Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 4Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 5Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 6Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 7Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 8Health News:Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2009 9Health News:Newly Published Research Indicates 97% of Apraxic Children Improving with Novel Nutritional Combination 2Health News:Newly Published Research Indicates 97% of Apraxic Children Improving with Novel Nutritional Combination 3Health News:Newly Published Research Indicates 97% of Apraxic Children Improving with Novel Nutritional Combination 4Health News:ENT and Allergy Opens New Office in Hoboken, New Jersey…Practice Achieves Milestone by Bringing on its 100th Physician 2Health News:ENT and Allergy Opens New Office in Hoboken, New Jersey…Practice Achieves Milestone by Bringing on its 100th Physician 3Health News:ENT and Allergy Opens New Office in Hoboken, New Jersey…Practice Achieves Milestone by Bringing on its 100th Physician 4
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless ... Robert F. Doman , Executive Chairman and Interim ... Noble Financial Capital Markets, Tenth Annual Equity Conference. ... corporate presentation to prospective corporate partners and investors ...
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ... price of $2.92 per share, net to the seller ...
(Date:1/14/2014)... , Jan. 14, 2014 ... ), a leading innovator of less invasive, miniaturized ... of advanced heart failure, today announced that it ... will be approximately $53 million, bringing expected full-year ... "Our full-year revenue growth of 87% for 2013 ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... up to 10 LPM of oxygen reducing the ... The M10 is engineered to reduce the cost ... has fewer parts than any other concentrator on ... help you to reduce expenditure on accessories and ...
... important to have a choice that fits your ... with innovative excellence, offers two great choices! Introducing ... value packed conservers., ,With its single AA ... hours a day for 3 to 4 weeks ...
... Get the equivalent of 7.5 liters out ... will you need two machines for your high-flow ... OXYMIZER Disposable Oxygen-Conserving Devices function like standard conservers, ... flow of oxygen required to saturate a patient. ...
The 24-Hour Oxygen Conserver....
Medicine Products: